Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density

FASEB Journal

Volumn 23, Issue 7, 2009, Pages 2176-2185

  Messaoudi, Smail ^a,b   Milliez, Paul ^a,c   Samuel, Jane Lise ^a,b   Delcayre, Claude ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CHU CÔTE DE NACRE   (France)

Author keywords

Hormone; Oxidative stress; Streptozotocin; Transgenic animal; VEGFa

Indexed keywords

ALDOSTERONE SYNTHASE; EPLERENONE; MINERALOCORTICOID RECEPTOR; STREPTOZOCIN; SUPEROXIDE; VASCULOTROPIN A; ALDOSTERONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CAPILLARY DENSITY; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLYCEMIC CONTROL; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; SYSTOLIC DYSFUNCTION; TISSUE LEVEL; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; CORONARY BLOOD VESSEL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HEART; HEART MUSCLE; PHYSIOLOGY; SYSTOLE;

ANIMALIA; MUS;

ALDOSTERONE; ANIMALS; CAPILLARIES; CORONARY VESSELS; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; HEART; MICE; MYOCARDIUM; RECEPTORS, MINERALOCORTICOID; SYSTOLE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT;

EID: 68549109739     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.08-125302     Document Type: Article

References (47)

1. Kannel, W. B., Hjortland, M., and Castelli, W. P. (1974) Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34, 29-34
2. Beckman, J. A., Creager, M. A., and Libby, P. (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570-2581 (Pubitemid 34517204)
3. Reaven, G. M., Lithell, H., and Landsberg, L. (1996) Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. 334, 374-381 (Pubitemid 26049592)
4. Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A. W., and Grishman, A. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595-602
5. Fang, Z. Y., Prins, J. B., and Marwick, T. H. (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25, 543-567 (Pubitemid 39096070)
6. Yoon, Y. S., Uchida, S., Masuo, O., Cejna, M., Park, J. S., Gwon, H. C., Kirchmair, R., Bahlman, F., Walter, D., Curry, C., Hanley, A., Isner, J. M., and Losordo, D. W. (2005) Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111, 2073-2085 (Pubitemid 40577902)
7. Delcayre, C., and Swynghedauw, B. (2002) Molecular mechanisms of myocardial remodeling. The role of aldosterone. J. Mol. Cell. Cardiol. 34, 1577-1584 (Pubitemid 36001997)
8. Davies, J. I., Band, M., Morris, A., and Struthers, A. D. (2004) Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 47, 1687-1694 (Pubitemid 40022402)
9. Michel, F., Ambroisine, M. L., Duriez, M., Delcayre, C., Levy, B. I., and Silvestre, J. S. (2004) Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 109, 1933-1937 (Pubitemid 38544481)
10. Garnier, A., Bendall, J. K., Fuchs, S., Escoubet, B., Rochais, F., Hoerter, J., Nehme, J., Ambroisine, M. L., De Angelis, N., Morineau, G., d'Estienne, P., Fischmeister, R., Heymes, C., Pinet, F., and Delcayre, C. (2004) Cardiac-specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110, 1819-1825
11. Subramaniam, A., Jones, W. K., Gulick, J., Wert, S., Neumann, J., and Robbins, J. (1991) Tissue-specific regulation of the alphamyosin heavy chain gene promoter in transgenic mice. J. Biol. Chem. 266, 24613-24620 (Pubitemid 21908985)
12. Ambroisine, M. L., Favre, J., Oliviero, P., Rodriguez, C., Gao, J., Thuillez, C., Samuel, J. L., Richard, V., and Delcayre, C. (2007) Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation 116, 2435-2443 (Pubitemid 350145078)
13. Milliez, P., Deangelis, N., Rucker-Martin, C., Leenhardt, A., Vicaut, E., Robidel, E., Beaufils, P., Delcayre, C., and Hatem, S. N. (2005) Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur. Heart. J. 26, 2193-2199 (Pubitemid 41408006)
14. Ratajczak, P., Oliviero, P., Marotte, F., Kolar, F., Ostadal, B., and Samuel, J. L. (2005) Expression and localization of caveolins during postnatal development in rat heart: implication of thyroid hormone. J. Appl. Physiol. 99, 244-251 (Pubitemid 40934489)
15. Dhalla, N. S., Liu, X., Panagia, V., and Takeda, N. (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc. Res. 40, 239-247 (Pubitemid 28506032)
16. Dalle-Donne, I., Aldini, G., Carini, M., Colombo, R., Rossi, R., and Milzani, A. (2006) Protein carbonylation, cellular dysfunction, and disease progression. J. Cell. Mol. Med. 10, 389-406 (Pubitemid 44870187)
17. Uhrenholt, T. R., Schjerning, J., Rasmussen, L. E., Hansen, P. B., Norregaard, R., Jensen, B. L., and Skott, O. (2004) Rapid non-genomic effects of aldosterone on rodent vascular function. Acta Physiol. Scand. 181, 415-419 (Pubitemid 39078837)
18. Strauer, B. E., Motz, W., Vogt, M., and Schwartzkopff, B. (1997) Impaired coronary flow reserve in NIDDM: a possible role for diabetic cardiopathy in humans. Diabetes 46(Suppl. 2), S119-S124 (Pubitemid 27377412)
19. Lai, L., Pen, A., Hu, Y., Ma, J., Chen, J., Hao, C. M., Gu, Y., and Lin, S. (2007) Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptor. Life Sci. 81, 570-576 (Pubitemid 47212237)
20. Tammela, T., Enholm, B., Alitalo, K., and Paavonen, K. (2005) The biology of vascular endothelial growth factors. Cardiovasc. Res. 65, 550-563 (Pubitemid 40138976)
21. Carmeliet, P., Ng, Y. S., Nuyens, D., Theilmeier, G., Brusselmans, K., Cornelissen, I., Ehler, E., Kakkar, V. V., Stalmans, I., Mattot, V., Perriard, J. C., Dewerchin, M., Flameng, W., Nagy, A., Lupu, F., Moons, L., Collen, D., D'Amore, P. A., and Shima, D. T. (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495-502 (Pubitemid 29220207)
22. Fiordaliso, F., Cuccovillo, I., Bianchi, R., Bai, A., Doni, M., Salio, M., De Angelis, N., Ghezzi, P., Latini, R., and Masson, S. (2006) Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci. 79, 121-129 (Pubitemid 43737057)
23. Asbun, J., and Villarreal, F. J. (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 47, 693-700 (Pubitemid 43243087)
24. Miric, G., Dallemagne, C., Endre, Z., Margolin, S., Taylor, S. M., and Brown, L. (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol. 133, 687-694 (Pubitemid 32642874)
25. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., and Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717
26. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., and Gatlin, M. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (Pubitemid 36384098)
27. Beggah, A. T., Escoubet, B., Puttini, S., Cailmail, S., Delage, V., Ouvrard-Pascaud, A., Bocchi, B., Peuchmaur, M., Delcayre, C., Farman, N., and Jaisser, F. (2002) Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 99, 7160-7165 (Pubitemid 34526272)
28. Young, M., and Funder, J. W. (2004) Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145, 3153-3157 (Pubitemid 38829985)
29. Nagata, K., Obata, K., Xu, J., Ichihara, S., Noda, A., Kimata, H., Kato, T., Izawa, H., Murohara, T., and Yokota, M. (2006) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47, 656-664 (Pubitemid 43740235)
30. Pitt, B. (1995) "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc. Drugs Ther. 9, 145-149
31. Staessen, J., Lijnen, P., Fagard, R., Verschueren, L. J., and Amery, A. (1981) Rise of plasma aldosterone during long-term captopril treatment. N. Engl. J. Med. 304, 1110
32. Fraccarollo, D., Galuppo, P., Hildemann, S., Christ, M., Ertl, G., and Bauersachs, J. (2003) Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J. Am. Coll. Cardiol. 42, 1666-1673 (Pubitemid 37378451)
33. Michel, J. B., Lattion, A. L., Salzmann, J. L., Cerol, M. L., Philippe, M., Camilleri, J. P., and Corvol, P. (1988) Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ. Res. 62, 641-650 (Pubitemid 18103224)
34. Pinto, Y. M., de Smet, B. G., van Gilst, W. H., Scholtens, E., Monnink, S., de Graeff, P. A., and Wesseling, H. (1993) Selective and time-related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc. Res. 27, 1933-1938 (Pubitemid 23357335)
35. Schunkert, H., Tang, S. S., Litwin, S. E., Diamant, D., Riegger, G., Dzau, V. J., and Ingelfinger, J. R. (1993) Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. Cardiovasc. Res. 27, 731-735 (Pubitemid 23162664)
36. Sun, Y., Ahokas, R. A., Bhattacharya, S. K., Gerling, I. C., Carbone, L. D., and Weber, K. T. (2006) Oxidative stress in aldosteronism. Cardiovasc. Res. 71, 300-309
37. Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A., McMahon, E. G., and Delyani, J. A. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802-H1810 (Pubitemid 35217013)
38. Schiffrin, E. L. (2006) Effects of aldosterone on the vasculature. Hypertension 47, 312-318
39. Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R. M., and Schiffrin, E. L. (2002) Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40, 504-510
40. Stewart, R. A., Kerr, A. J., Cowan, B. R., Young, A. A., Occleshaw, C., Richards, A. M., Edwards, C., Whalley, G. A., Freidlander, D., Williams, M., Doughty, R. N., Zeng, I., and White, H. D. (2008) A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am. Heart J. 156, 348-355
41. De Azevedo, M. J., Ramos, O. L., and Gross, J. L. (1995) Renin-aldosterone axis in normoalbuminuric insulin-dependent diabetes mellitus patients with glomerular hyperfiltration. Diabetes Res. Clin. Pract. 27, 205-210
42. Cronin, C. C., Barry, D., Crowley, B., and Ferriss, J. B. (1995) Reduced plasma aldosterone concentrations in randomly selected patients with insulin-dependent diabetes mellitus. Diabet. Med. 12, 809-815
43. Verma, S., Yuen, V. G., Badiwala, M., Anderson, T. J., and McNeill, J. H. (2003) Working heart function in diabetes is not improved by spironolactone treatment. Can. J. Physiol. Pharmacol. 81, 493-496 (Pubitemid 36605561)
44. McQueen, A. P., Zhang, D., Hu, P., Swenson, L., Yang, Y., Zaha, V. G., Hoffman, J. L., Yun, U. J., Chakrabarti, G., Wang, Z., Albertine, K. H., Abel, E. D., and Litwin, S. E. (2005) Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J. Mol. Cell. Cardiol. 39, 882-892 (Pubitemid 41572321)
45. Breyer, M. D., Bottinger, E., Brosius, F. C., 3rd, Coffman, T. M., Harris, R. C., Heilig, C. W., and Sharma, K. (2005) Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16, 27-45
46. Hsueh, W., Abel, E. D., Breslow, J. L., Maeda, N., Davis, R. C., Fisher, E. A., Dansky, H., McClain, D. A., McIndoe, R., Wassef, M. K., Rabadan-Diehl, C., and Goldberg, I. J. (2007) Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res. 100, 1415-1427 (Pubitemid 46834754)
47. Poornima, I. G., Parikh, P., and Shannon, R. P. (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98, 596-605 (Pubitemid 43755278)